DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/gcvcs5/noninvasive) has announced the addition of the "Non-Invasive Glucose Monitoring Patent Landscape" report to their offering.
The global glucose monitoring device market is estimated to reach $14 billion by 2019.
To this date, the conventional technique to measure glucose still involves drawing blood (finger pricking), which can cause pain and discomfort for the patient. Hence the need to find a non-invasive technique to monitor glucose. Many companies have tried to develop non-invasive technology and devices for glucose monitoring, but so far with no success.
A few devices had obtained approval from the authorities in the USA or Europe before being abandoned: GlucoWatch (Cygnus), Pendra (Pendragon Medical), NBM-200G (OrSense) or HG1-c (C8 MediSensors). Recently, Integrity Applications received the European CE Mark and launched its GlucoTrack DF-F device late 2014 in Europe. While several minimally-invasive devices are now commercially available, bringing to the market a totally non-invasive device would represent a great change for the market and diabetics.
The renewed IP interest for this topic observed recently shows the desire of players to overcome the same cause of failure faced in the last 3 decades, reliability and accuracy of the technology. The IP and the market for non-invasive monitoring of glucose are driven by the ever increasing diabetic population around the world as well as the recent sizeable democratization of wearable sensors for health monitoring. The spectrum of technologies investigated to monitor glucose non-invasively is very broad. Spectrometry is the most trendy technology. Spectrometry regroups various techniques, but they don't all receive the same focus. The spectrum of sample targets studied to perform a non-invasive measurement is also really broad.
The detection of glucose level at the skin level or in the blood vessels are the most investigated. But techniques allowing a detection at the level of the eye are also considered and a new comer in the non-invasive glucose monitoring domain is investing mostly in this approach.
Key Features Of The Report:
- Time evolution of patent publications and countries of patent filings
- Current legal status of patents
- Ranking of main patent applicants
- Joint developments and IP collaboration network of main patent applicants
- Key patents
- Granted patents near expiration
- Relative strength of main companies IP portfolio
- Non-invasive glucose monitoring IP profiles of 15 major companies with key patents, partnerships, and IP strength and strategy
- The report also provides an extensive Excel database with all patents analyzed in the study
Objective Of The Report:
- Understand the IP landscape for non-invasive glucose monitoring
- Identify key patents
- Understand trends in non-invasive glucose monitoring IP
- Classify the major players in noninvasive glucose monitoring IP and the relative strength of their patent portfolio
- Identify new players in non-invasive glucose monitoring IP
- Identify IP collaboration networks between key players
- Animas Technologies
- Bayer Healthcare
- InLight Solutions
- Integrity Applications
- Key Player Selection
- Roche Diagnostics
- Samsung Electronics
- Sensys Medical
For more information visit http://www.researchandmarkets.com/research/gcvcs5/noninvasive